18 recruiting, 14 unknown, 10 completed, 6 active not recruiting. 21 Not applicable, 11 Phase 2, 6 Phase 3, 6 Phase 4, 3 Phase 1.
Follow Focal Epilepsy: new trials by email Literature Review of Focal Epilepsy trials Research Report on Focal Epilepsy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| RNS System for Drug-Resistant Focal Epilepsy in Adolescents: A Real-World Study NeuroPace RNS System - Focal Epilepsy, Drug-resistant Focal Epilepsy | Enrolling by invitation | NeuroPace | 100 | 2026-09-14 | 2026-09-16 | |
| Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures RAP-219, Placebo - Focal Seizure, Epilepsy | Phase 3 | Recruiting | Rapport Therapeutics Inc. | 312 | 2026-09-01 | 2026-10-15 |
| High-density Flexible μECoG for Epilepsy Surgery - A Single-Arm ECT Using High-density Flexible microElectrocorticography for intraoperative monitoring - Focal Epilepsy, Intraoperative Monitoring | Not applicable | Recruiting | Beijing Tiantan Hospital | 85 | 2026-09-01 | 2026-08-13 |
| Efficacy of Probenecid on Cluster Seizures During Anti Seizure Medication Withdrawal in Presurgical Focal Epilepsy Video-EEG Monitoring Probenecid, Placebo - Focal Epilepsy | Phase 2 | Recruiting | Fondation Ophtalmologique Adolphe de Rothschild | 600 | 2026-08-24 | 2026-10-05 |
| Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1 RAP-219, Placebo - Focal Seizure, Epilepsy | Phase 3 | Recruiting | Rapport Therapeutics Inc. | 333 | 2026-06-05 | 2026-10-21 |
| Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures 40 mg/day vormatrogine for 12 weeks, 30 mg/day vormatrogine for 12 weeks, 20 mg/day vormatrogine for 12 weeks - Focal Epilepsy | Phase 3 | Active not recruiting | Praxis Precision Medicines | 300 | 2026-01-29 | 2026-08-03 |
| Optimizing Therapy in Epilepsy Using Seizure Forecasts Via EEG and Wearables UNEEG SubQ device, seizure forecasts, nasal diazepam, Preventative Medication (PM) - Focal Epilepsy, Generalized Seizure | Early Phase 1 | Recruiting | Mayo Clinic | 12 | 2026-01-20 | 2026-09-25 |
| A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures RAP-219 - Focal Epilepsy, Epilepsy | Phase 2 | Recruiting | Rapport Therapeutics Inc. | 30 | 2025-12-15 | 2026-01-23 |
| Thalamic Recordings in Children Undergoing SEEG Additional electrodes into bilateral anterior, centromedian and pulvinar thalamic nuclei - Focal Epilepsy | Not applicable | Recruiting | Great Ormond Street Hospital for Children NHS Foundation Trust | 30 | 2025-09-01 | 2026-02-02 |
| Butylphthalide for Cognitive Impairment in Elderly Patients With Focal Epilepsy Butylphthalide, Placebo - Focal Epilepsy, Cognitive Impairment | Phase 4 | Recruiting | First Affiliated Hospital of Wenzhou Medical University | 220 | 2025-09-01 | 2025-09-25 |
| An Open-label Study to Evaluate Safety, Tolerability, and Efficacy of CB03-154 in Subjects Diagnosed With Epilepsy CB03-154 - Focal Epilepsy | Phase 2 | Recruiting | Shanghai Zhimeng Biopharma, Inc. | 144 | 2025-08-14 | 2025-11-20 |
| Wearable Epileptic Seizure Prediction and Alert Glasses Based on Neuromorphic Computing Wearable seizure prediction and alert glasses - Epilepsy, Epileptic Seizures | Not applicable | Active not recruiting | Oman Ministry of Health | 47 | 2025-08-10 | 2025-10-07 |
| Sleep Architecture & Cognition in Focal Epilepsy Acoustic Stimulation (AS), SHAM Stimulation - Focal Epilepsy | Not applicable | Recruiting | University of California, Davis | 40 | 2025-01-24 | 2026-08-07 |
| Evaluation of New Flexible High-density Intra-operative ECoG Electrodes for Epilepsy Surgery. ( EpiGrid ) SOFT ECoG subdural grid electrode - Focal Epilepsy, Intraoperative Monitoring | Not applicable | Recruiting | Neurosoft Bioelectronics SA | 12 | 2025-01-01 | 2025-12-10 |
| Efficacy of Intersectional Short Pulse Stimulation for Terminating Seizures SeizureStop Device - Seizures, Focal Epilepsy | Not applicable | Withdrawn | NYU Langone Health | 2025-01-01 | 2024-12-30 | |
| A Study to Evaluate the Safety, Tolerability, and Efficacy of CB03-154 in Adult Patients With Focal Epilepsy Test drug CB03-154 5mg group, Test drug CB03-154 10mg group, Test drug CB03-154 20mg group - Focal Epilepsy | Phase 2 | Recruiting | Shanghai Zhimeng Biopharma, Inc. | 180 | 2024-08-14 | 2026-09-22 |
| Long-term Safety and Tolerability of BHV-7000 BHV-7000 - Focal Epilepsy | Phase 2 | Enrolling by invitation | Biohaven Therapeutics Ltd. | 660 | 2024-07-30 | 2026-05-01 |
| Spatial Scene Recognition Memory in Epilepsy Surgery Virtual Tour Recognition Memory Task, Intracranial EEG Recording with Research Electrodes (Aim III only), MRI Neuroimaging and Neuropsychological Assessment (Aim I) - Focal Epilepsy, Temporal Lobe Epilepsy | Not applicable | Recruiting | University of California, Davis | 620 | 2024-07-01 | 2026-05-12 |
| Cognitive Impairment in Drug-resistant and Drug-responsive Focal Cryptogenic Epilepsy Neuropsychological Assessment - Epilepsy, Focal Epilepsy | Recruiting | IRCCS San Raffaele | 130 | 2024-06-20 | 2024-06-24 | |
| Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy BHV-7000, Placebo - Focal Epilepsy | Phase 2 / Phase 3 | Active not recruiting | Biohaven Therapeutics Ltd. | 390 | 2024-05-13 | 2026-08-13 |
Showing 20 of 58. Sign in to see all of them.
Epilepsies, Partial (58) · Epilepsy (21) · Drug Resistant Epilepsy (13) · Seizures (13) · Epilepsy, Generalized (3) · Brain Diseases (1) · Central Nervous System Diseases (1) · Cognitive Dysfunction (1) · Epilepsy, Temporal Lobe (1) · Focal Cortical Dysplasia (1) · Lennox Gastaut Syndrome (1) · Memory Disorders (1) · Orientation, Spatial (1)
Nervous System Diseases (58) · Brain Diseases (57) · Central Nervous System Diseases (57) · Epilepsy (37) · Neurologic Manifestations (14) · Pathological Conditions, Signs and Symptoms (14) · Signs and Symptoms (14) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Epileptic Syndromes (2) · Behavior (1) · Cognition Disorders (1) · Congenital Abnormalities (1) · Genetic Diseases, Inborn (1) · Malformations of Cortical Development (1) · Malformations of Cortical Development, Group I (1)
Lamotrigine (3) · Levetiracetam (3) · Carbamazepine (2) · XEN1101 (2) · perampanel (2) · 3-n-butylphthalide (1) · Acoustic Stimulation (1) · Brain Mapping (1) · Dosage Forms (1) · Gabapentin (1) · Lacosamide (1) · Monitoring, Intraoperative (1) · Population Groups (1) · Pregabalin (1) · Probenecid (1)
Biohaven Therapeutics Ltd. (3) · Mayo Clinic (3) · Rapport Therapeutics Inc. (3) · Fondation Ophtalmologique Adolphe de Rothschild (2) · Great Ormond Street Hospital for Children NHS Foundation Trust (2) · NYU Langone Health (2) · NeuroPace (2) · Shanghai Zhimeng Biopharma, Inc. (2) · University of California, Davis (2) · Xenon Pharmaceuticals Inc. (2) · Aristotle University Of Thessaloniki (1) · Assistance Publique - Hôpitaux de Paris (1) · Beijing Tiantan Hospital (1) · Cerebral Therapeutics LLC (1) · Chinese University of Hong Kong (1)
United States (23) · France (12) · Australia (7) · Germany (6) · United Kingdom (6) · Italy (5) · Netherlands (5) · Poland (5) · Canada (4) · Hungary (4) · Spain (4) · Argentina (3) · Austria (3) · Belgium (3) · Chile (3)
Anli Liu, MD, MA (1) · Ashish Deshpande, MD (1) · Baptiste Morel (1) · Benjamin Brinkmann, PhD (1) · Brian Lundstrom, MD, PhD (1) · Cheolsu Shin, MD (1) · Daniel Lowenstein, MD (1) · Dr Mohammad Osman, MBBS (1) · Eugen Trinka, MD (1) · Gregory A Worrell, MD, PhD (1) · Ho Wan Leung (1) · Huiqin Xu, MD (1) · Imran Quraishi, MD (1)
PMID 22399764, PMID 23223279, PMID 24370818, PMID 25684224, PMID 25741734, PMID 25948717, PMID 27915117, PMID 32690786, PMID 37812429, PMID 40782718, PMID 40853673
2023 (3), 2018 (1), R01NS133743 (1), UG3NS123066-02 (1)